Ranibizumab biosimilar (Jieke biomedical)

雷珠单抗生物类似药（杰科生物）

Report date: 2026/02/06 20:01:23

Base Information

Drug NameRanibizumab biosimilar (Jieke biomedical)
Drug Alias NameJL14002JL-14002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesJecho Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJecho Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A